How Well the Vaccine Works
- Based on evidence from clinical trials in people ages 16 years and older, the Pfizer-BioNTech (COMIRNATY) vaccine was 95% effective at preventing laboratory-confirmed infection with the virus that causes COVID-19 in people who received two doses and had no evidence of being previously infected.
- In clinical trials, the Pfizer-BioNTech vaccine had >90% efficacy in preventing laboratory-confirmed COVID-19 infection in children ages 5–15 years, and the immune response in children ages 5–15 years was at least as strong as the immune response in people ages 16–25 years.
- In clinical trials, the vaccine also had >90% efficacy in preventing COVID-19 among people of diverse age, sex, race, and ethnicity categories and among people with underlying medical conditions.
- Evidence shows mRNA COVID-19 vaccines offer similar protection in real-world conditionsas they have in clinical trial settings―reducing the risk of COVID-19, including severe illness, by 90% or more among people who are fully vaccinated.